,date,information,related
0,2022-09-26,"Headline: Seagen, Lava Therapeutics enter worldwide license agreement for LAVA-1223, source:Thefly.com, summary: Seagen Inc. (SGEN) and LA... SGEN, LVTX, Headline: Seagen, Lava Therapeutics announce exclusive LAVA-1223 license agreement, source:Thefly.com, summary: Seagen (SGEN) and Lava Th... SGEN, LVTX, Headline: Lava Therapeutics Stock Soars After Commercialization Deal with Seagen, source:MarketWatch, summary: By Sabela Ojea Shares of LAVA Therapeutics NV doubled on premarket trading Monday after the biotechnology company said it has signed a global exclusive deal..., Headline: LAVA Therapeutics (NASDAQ:LVTX) Runs Hot on Seagen Deal, source:TipRanks, summary: Shares of clinical-stage oncology company LAVA Therapeutics (NASDAQ:LVTX) are soaring high today after its worldwide licensing deal with Seagen (NASDAQ:SGEN) for LA..., Headline: What Is Going on With Lava Therapeutics (LVTX) Stock Today?, source:InvestorPlace, summary: Lava Therapeutics (LVTX) stock is rocketing higher on Monday as investors react to an exclusive global license agreement with Seagen (SGEN)., Headline: Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors, source:Yahoo, summary: – Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate Vγ9Vδ2 (Gamma Delta) T Cells in the Presence of EGFR-Expressing Solid Tumors – – LAVA to Receive Upfront Payment of $50 Million, With Potential for Milestones of up to Approximately $650 Million and Royalties – – Seagen also has an Option to Nominate up to Two Additional Tumor Targets for Bispecifics using LAVA’s Proprietary Gammabody™ Platform – BOTHELL, Wash. and UTRECHT, The Netherland, Headline: Stocks making the biggest moves midday: Wynn Resorts, Planet Fitness, AMC, Lyft and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. ",SGEN
1,2022-09-27,"Headline: Seagen to be paid $30M up-front in Zai Lab deal for Tivdak development in China, source:Thefly.com, summary: Zai Lab Limited  (ZLAB) a... ZLAB, SGEN, GMAB, Headline: Seagen, Zai Lab enter regional collaboration, license agreement for TIVDAK, source:Thefly.com, summary: Zai Lab (ZLAB) and Seagen... ZLAB, SGEN, GMAB, Headline: IN BRIEF: Seagen to license Tivdak in China with help of Zai Lab, source:Alliance News, summary: No summary, Headline: Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv), source:Yahoo, summary: -- Zai Lab Obtains Exclusive Rights to Develop and Commercialize TIVDAK, an FDA-approved First-in-Class Antibody-Drug Conjugate (ADC), in Mainland China, Hong Kong, Macau, and Taiwan -- -- Zai Lab will Leverage its Leadership in Women’s Cancer in China to Commercialize and Expand Patient Access to TIVDAK -- -- Collaboration Supports Regional Patient Enrollment for InnovaTV 301, a Global Phase 3 Trial of TIVDAK in Patients with Recurrent or Metastatic Cervical Cancer -- SHANGHAI and CAMBRIDGE, Ma",SGEN
2,2022-09-28,"Headline: Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK (tisotumab vedotin-tftv), source:Finnhub, summary: BOTHELL, Wash. & SHANGHAI & CAMBRIDGE, Mass. - Seagen Inc. , a world leader and pioneer in antibody-drug conjugate therapies, and Zai Lab Limited , a patient-focused, innovative,... | September 28, 2022, Headline: Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK, source:Finnhub, summary: BOTHELL - Seagen Inc. , a world leader and pioneer in antibody-drug conjugate therapies, and Zai Lab Limited , a patient-focused, innovative, commercial-stage global biopharmaceutical company, today... | September 28, 2022, Headline: Tracking Baker Brothers Portfolio - Q2 2022 Update, source:SeekingAlpha, summary: Baker Brothersâ 13F portfolio value increased from $17.40B to $17.63B in Q2. Click here to read the portfolio's Q2 2022 Update.",SGEN
3,2022-09-29,"Headline: Cramer's lightning round: Charles River is a buy, source:CNBC, summary: ""Mad Money"" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.",SGEN
4,2022-09-30,"Headline: Seagen: Upcoming Short- And Medium-Term Clinical Catalysts, source:SeekingAlpha, summary: Seagen expects to complete six additional human trials in next 6 months. Check here to see SGEN's upcoming milestones and its development pipeline., Headline: Standalone Seagen Is Starting To Look Attractive, source:SeekingAlpha, summary: Seagen is starting to look attractive as a standalone entity, with the stock back to pre-buyout speculation levels. Read what investors need to know.",SGEN
5,2022-10-02,"Headline: Week In Review: YishengBio To List On Nasdaq Via SPAC Merger At An $834 Million Value, source:SeekingAlpha, summary: Beijing YishengBio will merge with SPAC vehicle Summit Healthcare Acquisition to list on Nasdaq. Sihuan Pharma subsidiary Xuanzhu Biopharm has filed for an IPO on the Shanghai STAR Exchange.",SGEN
6,2022-10-04,"Headline: Seagen: A Stellar Portfolio Anchor, source:SeekingAlpha, summary: As it successfully transitioned into a commercial-stage operator, Seagen is enjoying great progress. Click here to read how various catalysts would deliver much long-term upside.",SGEN
7,2022-10-06,"Headline: Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October 27, 2022, source:Yahoo, summary: BOTHELL, Wash., October 06, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its third quarter 2022 financial results on Thursday, October 27, 2022 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update.",SGEN
8,2022-10-07,"Headline: Biohaven Ltd. Surges 7.6%: Is This An Indication Of Further Gains? , source:TalkMarkets, summary: Biohaven Ltd. shares ended the last trading session 7.6% higher at $13.18. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the 91.8% loss over the past four weeks., Headline: Biohaven Ltd. (BHVN) Surges 7.6%: Is This an Indication of Further Gains?, source:Yahoo, summary: Biohaven Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.",SGEN
9,2022-10-09,"Headline: Big-Cap S&P Stocks Will Soon Provide Tech-Like Returns, I Explain, source:SeekingAlpha, summary: Learn more about an opportunity to acquire well-known big-cap names in the S&P 500 that, at this point, could provide ""tech-like"" returns.",SGEN
10,2022-10-11,"Headline: Seagen upgraded to Outperform from Market Perform at BMO Capital, source:Thefly.com, summary: BMO Capital analyst Etzer... SGEN, Headline: Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: Lululemon Athletica upgrade, Meta Platforms downgrade and Texas Instruments initiation among today's top calls on Wall Street LULU, NKE, ELF, NOW, ABC, SGEN, AMGN, META, QRVO, SWKS, ZM, FFIV, SPWR, TXN, SNOW, BA, SPLK, DT, DDOG, RBLX",SGEN
11,2022-10-13,"Headline: SGEN June 2023 Options Begin Trading, source:Stock Options Channel, summary: Staff article entitled SGEN June 2023 Options Begin Trading, about stock options, from Stock Options Channel.",SGEN
12,2022-10-14,"Headline: ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech, source:SeekingAlpha, summary: ORIC is a speculative Buy. Key risks include disappointing data for phase 1 readouts 1H23, delays in the clinic and heavy competition in certain areas. Read more.",SGEN
13,2022-10-17,"Headline: LAVA Therapeutics: Assessing A Promising Innovator, source:SeekingAlpha, summary: LAVA is able to form a highly profitable partnership with Seagen. Learn more why I recommend LVTX stock as a speculative/diversification buy.",SGEN
14,2022-10-19,"Headline: Investing in Seagen (NASDAQ:SGEN) five years ago would have delivered you a 116% gain, source:Yahoo, summary: Seagen Inc. ( NASDAQ:SGEN ) shareholders might be concerned after seeing the share price drop 22% in the last quarter...",SGEN
15,2022-10-20,"Headline: HQH: A Dividend Paymaster That Fails To Register Price Growth, source:SeekingAlpha, summary: Tekla Healthcare Investors is able to generate steady yield and currently trades at a good discount to its NAV. Read more to see why HQH is a Buy.",SGEN
16,2022-10-23,"Headline: I Called This October Rally In August, Keep Your Seat Belts On, source:SeekingAlpha, summary: After a barely discernible bottoming process, the rally has become obvious. Read more to see how I intend to take advantage of this rally.",SGEN
17,2022-10-24,"Headline: Seagen price target lowered to $155 from $194 at JPMorgan, source:Thefly.com, summary: JPMorgan analyst Jessica ... SGEN, Headline: Merck: A Shield From Recession, source:SeekingAlpha, summary: Despite healthcare giants succumbing to plunges, Merck is up 14.30%. Why do I believe MRK stock can provide a recession shield? Click here to find out.",SGEN
18,2022-10-25,"Headline: Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q3 Earnings Expected to Decline, source:Yahoo, summary: Rhythm Pharmaceuticals, Inc. (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",SGEN
19,2022-10-26,"Headline: Seagen reports Q3 EPS ($1.03), consensus (95c), source:Thefly.com, summary: Reports Q3 revenue $510.3... SGEN, Headline: Seagen raises FY22 revenue $1.82B-$1.865B from $1.71B-$1.795B, source:Thefly.com, summary: consensus $1.84B.... SGEN",SGEN
20,2022-10-27,"Headline: Seattle Genetics: Q3 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Seagen Reports Third Quarter 2022 Financial Results, source:Yahoo, summary: BOTHELL, Wash., October 27, 2022--Seagen Inc. (Nasdaq:SGEN) reported financial results today for the third quarter ended September 30, 2022. The Company also highlighted PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib), ADCETRIS® (brentuximab vedotin) and TIVDAK® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its deep and diverse oncology pipeline., Headline: Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates, source:Yahoo, summary: Seattle Genetics (SGEN) delivered earnings and revenue surprises of -11.96% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?, Headline: Seagen Inc. 2022 Q3 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by Seagen Inc., Headline: Seagen Inc. (SGEN) Q3 2022 Earnings Call Transcript, source:SeekingAlpha, summary: Seagen Inc. (NASDAQ:NASDAQ:SGEN) Q3 2022 Earnings Conference Call October 27, 2022 16:30 ET Company Participants Doug Maffei - Vice President, Investor Relations Roger Dansey - Interim...",SGEN
21,2022-10-28,"Headline: Seagen price target lowered to $180 from $200 at H.C. Wainwright, source:Thefly.com, summary: H.C. Wainwright analyst A... SGEN, Headline: H.C. Wainwright Sticks to Its Buy Rating for Seagen (SGEN), source:TipRanks, summary: No summary, Headline: Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY) and Seagen (SGEN), source:TipRanks, summary: No summary, Headline: Top 5 3rd Quarter Trades of La - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Top 5 3rd Quarter Trades of Lattice Capital Management, LLC, source:GuruFocus, summary: No summary, Headline: Morgan Stanley Reaffirms Their Buy Rating on Seagen (SGEN), source:TipRanks, summary: No summary",SGEN
22,2022-10-30,"Headline: Analysts’ Opinions Are Mixed on These Healthcare Stocks: Seagen (SGEN), Alnylam Pharma (ALNY) and BioMarin Pharmaceutical (BMRN), source:TipRanks, summary: Analysts have been eager to weigh in on the Healthcare sector with new ratings on Seagen (<a href..., Headline: Analysts` Opinions Are Mixed on These Healthcare Stocks: Seagen (SGEN), Alnylam Pharma (ALNY) and BioMarin Pharmaceutical (BMRN), source:TipRanks, summary: No summary, Headline: Merck: Great Medicine For The Portfolio, source:SeekingAlpha, summary: Merck has seen strong growth so far this year, even if we strip out the pandemic-related contribution. Read why MRK shares may look good for a long-term setup.",SGEN
23,2022-10-31,"Headline: Final Trades: Honeywell, XPO Logistics, Seagen & more, source:CNBC, summary: The ""Halftime Report"" traders give their top picks to watch for the second half.",SGEN
24,2022-11-02,"Headline: JMP Securities Sticks to Their Buy Rating for Seagen (SGEN), source:TipRanks, summary: No summary",SGEN
25,2022-11-03,"Headline: Genmab: Great Company, But Stock Is Not That Great, source:SeekingAlpha, summary: Genmab, as a company, has brought valuable medicines for patients. However, as a stock, it seems to be lagging. See why.",SGEN
26,2022-11-07,"Headline: Society for Immunotherapy of Cancer to hold a meeting, source:Thefly.com, summary: No summary",SGEN
27,2022-11-09,"Headline: Seagen Larger Than S&P 500 Component Kellogg, source:The Online Investor, summary: No summary",SGEN
28,2022-11-10,"Headline: Seagen appoints former Novartis cancer czar as CEO, source:Seeking Alpha, summary: No summary, Headline: Seagen appoints David Epstein as CEO, source:Thefly.com, summary: No summary, Headline: Video: Nasdaq 100 Movers: SGEN, TEAM, source:Market News Video, summary: No summary, Headline: Seagen Shares Fall 5.6% After David Epstein Named as CEO, source:MarketWatch, summary: By Kathryn Hardison Shares of Seagen Inc. fell 5.6% to $130.27 on Thursday after it said David Epstein was appointed as its next chief executive officer and..., Headline: Seagen Names David R. Epstein as Chief Executive Officer and Director, source:Yahoo, summary: BOTHELL, Wash., November 10, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that its Board of Directors has appointed David R. Epstein as Chief Executive Officer (CEO) and a member of the Board of Directors. Mr. Epstein brings more than 30 years of experience in the biopharmaceutical industry, including more than 25 years at Novartis where he built its oncology business unit from initiation to second largest in the world and then served as CEO of Novartis Pharmaceuticals, a division of Novarti, Headline: Seagen Appoints Sandra M. Swain, M.D., to Board of Directors, source:Yahoo, summary: BOTHELL, Wash., November 10, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that Sandra M. Swain, M.D., has been appointed to the company’s Board of Directors. Dr. Swain has more than 30 years of breast cancer clinical research experience. She currently serves as Associate Dean for Research Development and Professor of Medicine at Georgetown University Medical Center and is the Vice President of Genetic Medicine for MedStar Health. She is also on the Conquer Cancer Foundation Board of American, Headline: Seagen announces FDA approval for Adcetris in new indication, source:Thefly.com, summary: No summary, Headline: Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting, source:Yahoo, summary: BOTHELL, Wash., November 10, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that data from the company’s diverse pipeline of targeted cancer therapy candidates will be presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting being held November 8-12 in Boston. The presentations highlight data from multiple ongoing clinical and preclinical research studies that employ Seagen’s proprietary antibody-drug conjugate (ADC) technology, as well as other novel cancer targeting appro, Headline: Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma, source:Yahoo, summary: BOTHELL, Wash., November 10, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS® (brentuximab vedotin) for the treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide. The approval is based on data from a phase 3 study (AHOD1331) conducted by the Children's Oncology Group (COG, Headline: Society for Immunotherapy of Cancer to hold a meeting, source:Thefly.com, summary: No summary",SGEN
29,2022-11-11,"Headline: Seagen names new CEO following May resignation of Clay Siegall, source:Yahoo, summary: David Epstein spent more than 25 years at the Swiss pharmaceutical giant Novartis, where he helped build its oncology business., Headline: Society for Immunotherapy of Cancer to hold a meeting, source:Thefly.com, summary: No summary",SGEN
30,2022-11-13,"Headline: Seagen (SGEN) Receives a Buy from SVB Securities, source:TipRanks, summary: No summary, Headline: Did You Buy And Not Sell Friday? You`re Doing It Wrong - Again, source:Seeking Alpha, summary: No summary, Headline: Did You Buy And Not Sell Friday? You're Doing It Wrong - Again, source:SeekingAlpha, summary: This week saw quite a bit of volatility yet the VIX continues to fall. Read more to see why I expect this week we will see quite a comedown.",SGEN
31,2022-11-14,"Headline: Seagen director Gryska sells 7,500 common shares, source:Thefly.com, summary: No summary",SGEN
32,2022-11-16,"Headline: Seagen (SGEN) Receives a Buy from RBC Capital, source:TipRanks, summary: No summary",SGEN
33,2022-11-17,"Headline: Institutional owners may consider drastic measures as Seagen Inc.'s (NASDAQ:SGEN) recent US$1.2b drop adds to long-term losses, source:Yahoo, summary: To get a sense of who is truly in control of Seagen Inc. ( NASDAQ:SGEN ), it is important to understand the ownership...",SGEN
34,2022-11-21,"Headline: Seagen initiated with a Hold at Truist, source:Thefly.com, summary: No summary, Headline: Truist starts Seagen at Hold on concerns around Tukysa and Tivdak, source:Thefly.com, summary: No summary, Headline: Imago climbs 105% as Merck agrees to acquire for over $1B in cash, source:Seeking Alpha, summary: No summary, Headline: Seagen initiated Hold at Truist citing competitive headwinds, source:Seeking Alpha, summary: No summary",SGEN
35,2022-11-22,"Headline: Merck Vs. AbbVie: Which Is Better Buy As The Patent Cliffs Approach?, source:SeekingAlpha, summary: I will be comparing AbbVie and Merck to see which is better positioned for its patent cliff. Read to know why I like AbbVie more than Merck.",SGEN
36,2022-11-28,"Headline: Roche bladder cancer indication withdrawal positive for Seagen, says Guggenheim, source:Thefly.com, summary: No summary",SGEN
37,2022-11-30,"Headline: Genmab: Darzalex Continues To Impress, Epcoritamab One Step Closer To Market, source:SeekingAlpha, summary: The valuation is more demanding after the recent rally, but Genmab still looks well-positioned to deliver long-term growth. Click here to read our analysis of GMAB.",SGEN
38,2022-12-01,"Headline: Seagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting, source:Yahoo, summary: BOTHELL, Wash., December 01, 2022--Seagen Inc. (Nasdaq: SGEN) today announced new data for ADCETRIS® (brentuximab vedotin) will be featured at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 10-13, 2022. The abstracts, including five oral presentations, highlight updated and interim efficacy and safety clinical trial results for ADCETRIS in both early- and advanced stage settings of classical Hodgkin lymphoma (cHL), and in patients with",SGEN
39,2022-12-02,"Headline: BBH: Portfolio Of Large-Cap Biotechnology Stocks Has Delivered Strong Returns, source:SeekingAlpha, summary: BBH has an asset base of $520 million, posted strong growth over the past 6 months, and is trading much higher than its pre-pandemic price range. Click here to learn more.",SGEN
40,2022-12-07,"Headline: Seagen Inc.'s (NASDAQ:SGEN) Intrinsic Value Is Potentially 98% Above Its Share Price, source:Yahoo, summary: Does the December share price for Seagen Inc. ( NASDAQ:SGEN ) reflect what it's really worth? Today, we will estimate...",SGEN
41,2022-12-12,"Headline: Seagen announces results from Phase 2 trial of ADCETRIS, source:Thefly.com, summary: No summary, Headline: Seagen buoyed by Adcetris combo data for classical Hodgkin lymphoma, source:Seeking Alpha, summary: No summary, Headline: Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma, source:Yahoo, summary: BOTHELL, Wash., December 12, 2022--Seagen Inc. (Nasdaq: SGEN) today announced results from two parts of a phase 2 trial (SGN35-027) evaluating ADCETRIS® (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (AN+AD) for the frontline treatment of patients with classical Hodgkin lymphoma (cHL). Part B of the trial evaluated patients with advanced-stage disease and was presented as an oral presentation, and Part C evaluat, Headline: Zai Labs: Biopharma`s Alibaba, But Better, source:Seeking Alpha, summary: No summary",SGEN
42,2022-12-13,"Headline: Zai Labs: Biopharma's Alibaba, But Better, source:SeekingAlpha, summary: Zai Labs is a relative new entrant to the Chinese pharma space and has multiple approvals and a large clinical pipeline. Read more on ZLAB here., Headline: Seagen (SGEN) Gets a Buy from JMP Securities, source:TipRanks, summary: No summary",SGEN
43,2022-12-20,"Headline: Seagen, Astellas and Merck announce FDA acceptance of sBLA in urothelial cancer, source:Thefly.com, summary: No summary, Headline: Astellas, Seagen, and Merck announce priority review for Padcev and Keytruda, source:Thefly.com, summary: No summary, Headline: Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer, source:Yahoo, summary: Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., ""Astellas""), Seagen Inc. (Nasdaq: SGEN) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review supplemental Biologics License Applications (sBLAs) for PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) for use of these two agents in combination for the treatment of patients with locally advanced o, Headline: Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer, source:Yahoo, summary: BOTHELL, Wash. & TOKYO & RAHWAY, N.J., December 20, 2022--Seagen Inc. (Nasdaq: SGEN), Astellas Pharma Inc. (TSE:4503) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review supplemental Biologics License Applications (sBLAs) for PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) for use of these two agents in combination for the treatment of patients with locally advanc, Headline: Seagen to Present at the J.P. Morgan Healthcare Conference, source:Yahoo, summary: BOTHELL, Wash., December 20, 2022--Seagen Inc. (Nasdaq:SGEN) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 3:00 p.m. Pacific Time. The presentation will be webcast live and available for replay from the investor section of Seagen’s website at investor.seagen.com., Headline: FDA accepts Astellas, Seagen and Merck's combo for priority review, source:Alliance News, summary: No summary",SGEN
44,2022-12-22,"Headline: Seagen: 2023 Shaping Up To Be A Breakout Year, source:SeekingAlpha, summary: Seagen has been under pressure since a rumored takeover deal by pharmaceutical giant Merck & Co. fell through last summer. Read what investors need to know.",SGEN
45,2022-12-23,"Headline: This Insider Just Sold Shares of Seagen Inc, source:GuruFocus, summary: No summary",SGEN
46,2022-12-28,"Headline: We're Not Worried About Seagen's (NASDAQ:SGEN) Cash Burn, source:Yahoo, summary: Just because a business does not make any money, does not mean that the stock will go down. For example, although...",SGEN
47,2022-12-30,"Headline: Merck is best performing large U.S. pharma of 2022, source:Seeking Alpha, summary: No summary",SGEN
48,2023-01-02,"Headline: Merck Is Poised To Outperform In 2023, source:SeekingAlpha, summary: Merck substantially outperformed in 2022 and achieved a series of positive trial outcomes. See why I am maintaining a buy rating on MRK stock.",SGEN
49,2023-01-05,"Headline: Tracking Baker Brothers Portfolio - Q3 2022 Update, source:SeekingAlpha, summary: Baker Brothers' 13F portfolio value decreased from $17.63B to $15.27B this quarter. Find out the ongoing analysis of the changes made to the portfolio on a quarterly basis.",SGEN
50,2023-01-06,"Headline: AstraZeneca And Daiichi Sankyo`s Zauberkugel (Magic Bullet), source:Seeking Alpha, summary: No summary, Headline: AstraZeneca And Daiichi Sankyo's Zauberkugel (Magic Bullet), source:SeekingAlpha, summary: AstraZeneca, Daiichi Sankyo to market HER-2 cancer domain targeting therapy Enhertu. See why I consider accumulating DSKYF stock for Enhertu momentum play.",SGEN
51,2023-01-14,"Headline: Stocks To Watch: Economic Reports, Earnings Blockbusters And Political Minefields Lie Ahead Next Week, source:SeekingAlpha, summary: Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week",SGEN
52,2023-01-19,"Headline: Seagen (SGEN) Presents At 41st Annual Healthcare Conference - Slideshow, source:SeekingAlpha, summary: The following slide deck was published by Seagen Inc., Headline: Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023, source:Yahoo, summary: BOTHELL, Wash., January 19, 2023--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update., Headline: Seagen Gets FDA Accelerated Approval for Tukysa, source:MarketWatch, summary: By Kathryn Hardison Seagen Inc. said Thursday that the Food and Drug Administration has granted accelerated approval to Tukysa(R)tucatinib in combination..., Headline: Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer, source:Yahoo, summary: BOTHELL, Wash., January 19, 2023--Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TUKYSA® (tucatinib) in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. TUKYSA is approved under the FDA’s Accelerated Approval Program based on tum",SGEN
53,2023-01-20,"Headline: Biotech Alert: Searches spiking for these stocks today, source:Thefly.com, summary: No summary",SGEN
54,2023-01-22,"Headline: Global drug spending to reach $1.9T by 2027 ��� IQVIA, source:Seeking Alpha, summary: No summary",SGEN
55,2023-01-24,"Headline: Seagen (SGEN) Receives a Buy from Berenberg Bank, source:TipRanks, summary: No summary, Headline: Morgan Stanley Sticks to Its Buy Rating for Seagen (SGEN), source:TipRanks, summary: No summary",SGEN
56,2023-01-25,"Headline: Seagen price target lowered to $170 from $183 at Berenberg, source:Thefly.com, summary: No summary",SGEN
57,2023-01-30,"Headline: Truist sees potential pressure on Seagen`s Padcev in Q4, source:Thefly.com, summary: No summary, Headline: Seagen: Back On Track, Priced About Right, source:SeekingAlpha, summary: Seagen has a platform that can create new product candidates and can get some through the clinical process and into commercial sales. Find out why SGEN stock is a Hold.",SGEN
58,2023-01-31,"Headline: Genmab: High-Quality Biotech Darling, But Lacks Meaningful Catalysts In The Near Term, source:Seeking Alpha, summary: No summary",SGEN
59,2023-02-06,"Headline: Seagen downgraded to Market Perform from Outperform at SVB Securities, source:Thefly.com, summary: No summary, Headline: SVB Securities downgrades Seagen to Market Perform, lowers price target to $141, source:Thefly.com, summary: No summary, Headline: Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Regeneron (REGN) and Seagen (SGEN), source:TipRanks, summary: No summary",SGEN
60,2023-02-08,"Headline: Analysts Estimate Seattle Genetics (SGEN) to Report a Decline in Earnings: What to Look Out for, source:Yahoo, summary: Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: SVB Leerink Downgrades Seattle Genetics (SGEN), source:Fintel, summary: nan",SGEN
61,2023-02-09,"Headline: Top 5 4th Quarter Trades of Lattice Capital Management, LLC, source:GuruFocus, summary: No summary, Headline: Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?, source:Yahoo, summary: Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",SGEN
62,2023-02-10,"Headline: Jefferies biotechnology analyst to hold an analyst/industry conference call, source:Thefly.com, summary: No summary",SGEN
63,2023-02-12,"Headline: Seagen treatment of esophageal cancer granted orphan designation, source:Thefly.com, summary: No summary",SGEN
64,2023-02-13,"Headline: 3 Stocks to Buy Today, 2/13/2023, According to Top Analysts, source:TipRanks, summary: No summary, Headline: Analysts` Opinions Are Mixed on These Healthcare Stocks: Mettler-Toledo (MTD), Seagen (SGEN) and Nurix Therapeutics (NRIX), source:TipRanks, summary: No summary, Headline: Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, source:Yahoo, summary: BOTHELL, Wash., February 13, 2023--Seagen Inc. (Nasdaq: SGEN) today announced the presentation of new data featuring PADCEV® (enfortumab vedotin-ejfv) at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) taking place from February 16-18, 2023. A podium presentation will feature noteworthy patient-reported outcomes from the registrational Phase 1b/2 EV‐103 Cohort K study., Headline: Seattle Genetics Q4 2022 Earnings Preview, source:Seeking Alpha, summary: No summary, Headline: Notable earnings after Wednesday`s close, source:Seeking Alpha, summary: No summary",SGEN
65,2023-02-14,"Headline: Seagen (SGEN) Receives a Buy from BMO Capital, source:TipRanks, summary: No summary, Headline: GLOBAL BRIEFING: Stocks called lower ahead of UK inflation figures, source:Alliance News, summary: No summary, Headline: Seagen reports Q4 EPS (80c), consensus ($1.04), source:Thefly.com, summary: No summary, Headline: Seagen sees FY23 revenue $2.14B-$2.24B, consensus $2.3B, source:Thefly.com, summary: No summary, Headline: Seattle Genetics GAAP EPS of -$0.80 beats by $0.25, revenue of $528M beats by $48.19M, source:Seeking Alpha, summary: No summary",SGEN
66,2023-02-15,"Headline: Seagen up 6% on quarterly beats, though 2023 revenue outlook comes in below consensus, source:Seeking Alpha, summary: No summary, Headline: Fly Intel: After-Hours Movers, source:Thefly.com, summary: No summary, Headline: Cellectar Biosciences hires Shustov as new Senior Vice President, Medical, source:Thefly.com, summary: No summary, Headline: Seattle Genetics: Q4 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Seagen Reports Fourth Quarter and Full Year 2022 Financial Results, source:Yahoo, summary: BOTHELL, Wash., February 15, 2023--Seagen Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2022. The Company also highlighted PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib), ADCETRIS® (brentuximab vedotin) and TIVDAK® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its potentially transformative oncology pipeline., Headline: Seagen Inc. (SGEN) Q4 2022 Earnings Call Transcript, source:SeekingAlpha, summary: Seagen Inc. (NASDAQ:NASDAQ:SGEN) Q4 2022 Results Conference Call February 15, 2023 4:30 PM ETCompany ParticipantsDoug Maffei - VP, IRDavid Epstein - CEOChip Romp - EVP, Commercial U.S.Todd..., Headline: Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates, source:Yahoo, summary: Seattle Genetics (SGEN) delivered earnings and revenue surprises of 21.57% and 9.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?, Headline: Positive Report for Seagen (SGEN) from Raymond James, source:TipRanks, summary: No summary, Headline: Seagen nears six-month high as Wall Street cheers Q4 results, source:Seeking Alpha, summary: No summary, Headline: Seagen upgraded to Strong Buy from Outperform at Raymond James, source:Thefly.com, summary: No summary, Headline: Analysts Conflicted on These Healthcare Names: Amedisys (AMED), Seagen (SGEN) and Waters (WAT), source:TipRanks, summary: No summary",SGEN
67,2023-02-16,"Headline: Analysts Are Bullish on Top Healthcare Stocks: Prophase Labs (PRPH), Seagen (SGEN), source:TipRanks, summary: No summary, Headline: Berenberg Bank Remains a Buy on Seagen (SGEN), source:TipRanks, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Seagen (SGEN), source:TipRanks, summary: No summary, Headline: Seagen upgraded to Outperform from In Line at Evercore ISI, source:Thefly.com, summary: No summary, Headline: Seattle Genetics: Q4 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Seagen (SGEN) and Waters (WAT), source:TipRanks, summary: No summary, Headline: S&P 500 Futures Decline in Premarket Trading; Twilio, Roku Lead, source:MarketWatch, summary: With U.S. stock markets set to open in two hours, (TWLO) was up 14.9% in pre-market trading, and (ROKU) was up 11.6%. (CROX), (SGEN), and (TECK) were all..., Headline: Seagen price target raised to $155 from $145 at RBC Capital, source:Thefly.com, summary: No summary, Headline: Seagen (SGEN) Shares Cross Above 200 DMA, source:Market News Video, summary: No summary, Headline: Evercore ISI Group Upgrades Seattle Genetics (SGEN), source:Fintel, summary: nan, Headline: Raymond James Upgrades Seattle Genetics (SGEN), source:Fintel, summary: nan, Headline: Why Seattle Genetics, Alkermes Are Currently Outperforming Their Peers, source:Yahoo, summary: Seattle Genetics and Alkermes beat fourth-quarter estimates Thursday, pushing Alkermes stock into a brief breakout as SGEN stock soared., Headline: Seagen price target raised to $168 from $142 at JMP Securities, source:Thefly.com, summary: No summary",SGEN
68,2023-02-17,"Headline: SGEN Crosses Above Average Analyst Target, source:ETF Channel, summary: No summary, Headline: Seagen price target raised to $152 from $135 at Truist, source:Thefly.com, summary: No summary, Headline: SVB Securities Remains a Hold on Seagen (SGEN), source:TipRanks, summary: No summary, Headline: Seagen Full Year 2022 Earnings: Beats Expectations, source:Yahoo, summary: Seagen ( NASDAQ:SGEN ) Full Year 2022 Results Key Financial Results Revenue: US$1.96b (up 25% from FY 2021). Net loss..., Headline: Ghost Tree Capital, LLC Buys 3, Sells 2 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: JMP Securities Sticks to Its Buy Rating for Seagen (SGEN), source:TipRanks, summary: No summary",SGEN
69,2023-02-21,"Headline: Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Seagen (SGEN), source:TipRanks, summary: No summary, Headline: We're Not Worried About Seagen's (NASDAQ:SGEN) Cash Burn, source:Yahoo, summary: Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...",SGEN
70,2023-02-22,"Headline: Merck & Co.: Running A Bit Hot, source:SeekingAlpha, summary: Merck has seen a significant valuation re-rating take place over the past years. This comes amidst the success of Keytruda which creates some dependency risks as well. Read more here.",SGEN
71,2023-02-23,"Headline: Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Seagen (SGEN) and Denali Therapeutics (DNLI), source:TipRanks, summary: No summary, Headline: Seagen price target raised to $178 from $160 at Needham, source:Thefly.com, summary: No summary",SGEN
72,2023-02-25,"Headline: A Seagen Inc. (NASDAQ:SGEN) insider lowered their holding by 16% earlier this year, source:Yahoo, summary: Insiders were net sellers of Seagen Inc.'s ( NASDAQ:SGEN ) stock during the past year. That is, insiders sold more...",SGEN
73,2023-02-26,"Headline: Pfizer said in early-stake talks to acquire Seagen - WSJ, source:Seeking Alpha, summary: No summary, Headline: Pfizer said in early stage talks to acquire Seagen - WSJ, source:Seeking Alpha, summary: No summary, Headline: Pfizer eyes takeover of biotech Seagen, at value of more than $30 billion, source:MarketWatch, summary: Pfizer Inc. is in talks to acquire biotech Seagen Inc., according to people familiar with the matter, the latest potential deal for a big drug company aimed..., Headline: Pfizer Is Eyeing a Deal With Seagen After Merck`s Failure, source:GuruFocus, summary: No summary, Headline: Nasdaq, S&P, Dow headed for positive finish after their worst weekly loss in 2023, source:Seeking Alpha, summary: No summary, Headline: Pfizer in Talks to Acquire Seagen in Deal Likely Valued at More Than $30 Billion, source:Yahoo, summary: The potential deal, likely valued at more than $30 billion, would help Pfizer add to its lineup of cancer treatments., Headline: BRIEF-Pfizer In Early-Stage Talks To Acquire Seagen - WSJ, source:Reuters, summary: * PFIZER IN EARLY-STAGE TALKS TO ACQUIRE SEAGEN - WSJ Source text: [ https://on.wsj.com/41vkCnW ], Headline: What You Missed On Wall Street On Monday, source:Thefly.com, summary: No summary, Headline: Pfizer in talks to buy Seagen for likely for more than $30 bln - WSJ, source:Reuters, summary: Pfizer Inc is in early talks to acquire drugmaker Seagen Inc, the Wall Street Journal reported late on Sunday, citing people familiar with the matter., Headline: Pfizer in talks to buy Seagen for likely for more than $30 billion - WSJ, source:Reuters, summary: Pfizer Inc is in early talks to acquire drugmaker Seagen Inc, the Wall Street Journal reported late on Sunday, citing people familiar with the matter., Headline: Pfizer (NYSE:PFE) Could Buy Seagen; Bolster its Product Portfolio, source:TipRanks, summary: No summary, Headline: Pfizer in Talks to Buy Seagen for $30 Billion or More, source:MarketWatch, summary: The deal would strengthen Pfizer's lineup of cancer treatments, The Wall Street Journal reports., Headline: Pfizer (NYSE:PFE) Could Buy Seagen; Bolster its Oncology Portfolio, source:TipRanks, summary: No summary, Headline: Pfizer in talks to buy Seagen in deal that may be valued at over $30B, WSJ says, source:Thefly.com, summary: No summary, Headline: Hot Stocks: SGEN climbs on takeover interest; PFE sets 52-week low; TGNA drops; KOS hits 52-week high, source:Seeking Alpha, summary: No summary",SGEN
74,2023-02-27,"Headline: Pfizer (NYSE:PFE) Could Buy Seagen to Bolster Oncology Portfolio, source:TipRanks, summary: No summary, Headline: These Stocks Are Moving the Most Today: Fisker, Seagen, Tesla, FuboTV, Enphase, and More, source:MarketWatch, summary: Fisker says it still expects to build and ship around 42,000 units in 2023. A report says Pfizer is in discussions to acquire biotechnology company Seagen., Headline: Nasdaq, S&P, Dow futures rise with durable goods orders in view, source:Seeking Alpha, summary: No summary, Headline: Today`s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday, source:InvestorPlace, summary: No summary, Headline: Seagen`s stock soars on reported Pfizer buyout interest; Union Pacific shares rally after CEO ouster, source:MarketWatch, summary: No summary, Headline: S&P 500 Futures Up in Premarket Trading; Seagen, Union Pacific Lead, source:MarketWatch, summary: With U.S. stock markets set to open in two hours, (SGEN) was up 14.4% in pre-market trading, and (UNP) was up 10.0%. (AES), (TREX), and (AVTR) were all..., Headline: Nasdaq, S&P, Dow futures add to gains after durable goods orders plunge, source:Seeking Alpha, summary: No summary, Headline: Tesla, Seagen, Fisker and Union Pacific shares pop — and more stock-market movers, source:MarketWatch, summary: Here are some of the most active stocks in morning trading Monday, as the S&P 500 was headed higher., Headline: Stocks making the biggest moves premarket: Best Buy, Seagen, Union Pacific and more, source:CNBC, summary: Shares of Union Pacific rose 9.5% after the company said CEO Lance Fritz would have a successor named this year. , Headline: Pfizer acquisition of Seagen could add $7B in sales, says JPMorgan, source:Thefly.com, summary: No summary, Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: No summary, Headline: Seagen, Union Pacific and Tesla rise premarket; Pfizer falls, source:Yahoo, summary: By Peter Nurse, Headline: Nasdaq, S&P, Dow rally after durable goods orders plunge, source:Seeking Alpha, summary: No summary, Headline: The $30 Billion Reason Seagen (SGEN) Stock Is Up 11% Today, source:InvestorPlace, summary: No summary, Headline: UNP Stock Alert: What to Know as Union Pacific`s CEO Steps Down, source:InvestorPlace, summary: No summary, Headline: Pfizer in talks to buy cancer drugmaker Seagen - WSJ, source:Reuters, summary: Pfizer Inc is in early-stage talks to acquire cancer drugmaker Seagen Inc in what could be a multi-billion dollar deal, the Wall Street Journal reported on Sunday, citing people familiar with the matter., Headline: Pfizer-Seagen: Dividend Risk Evaluation, source:SeekingAlpha, summary: Pfizer Inc. is reportedly in early negotiations to acquire cancer-focused biotech Seagen Inc. Click here to read for my take on PFE's deal for SGEN., Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Stocks making the biggest moves midday: Union Pacific, Fisker, Tesla, Zillow and more, source:CNBC, summary: Union Pacific soared on news of a leadership change., Headline: Nasdaq, S&P, Dow rebound after suffering their worst weekly loss in 2023, source:Seeking Alpha, summary: No summary, Headline: Seagen to Present at the Cowen 43rd Annual Health Care Conference, source:Yahoo, summary: BOTHELL, Wash., February 27, 2023--Seagen Inc. (Nasdaq:SGEN) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 1:30 p.m. Eastern Time. The presentation will be webcast live and available for replay from the investor section of Seagen’s website at investor.seagen.com., Headline: Pfizer in talks to acquire biotech firm Seagen for $30 billion: Report, source:Yahoo, summary: Yahoo Finance Live’s Julie Hyman reports that Pfizer is looking to acquire biotech firm Seagen in a $30 billion takeover deal., Headline: Pfizer Needs The Seagen Deal, source:SeekingAlpha, summary: Pfizer has been reported as bidding for Seagen, competing with Merck & Co. Check out is this a good deal for PFE and SGEN shareholders., Headline: Tesla’s Investor Day, Warren Buffett’s letter to shareholders, Pfizer-Seagen deal: 3 things to know, source:Yahoo, summary: Yahoo Finance Live’s Brad Smith summarizes three key topics in markets to pay attention to on Monday morning., Headline: Seagen Stock Jumps After Pfizer Deal Report, source:Yahoo, summary: Shares of Seagen rose Monday morning after the Journal reported that drug giant [Pfizer was in talks](https://www.wsj.com/articles/pfizer-in-early-stage-talks-to-acquire-seagen-3f53309e) to acquire the biotechnology company. Seagen shares were recently ahead about 11%, while Pfizer's were off 1%. The talks are at an early stage and there is no guarantee there will be a deal, the Journal reported. Read today's [full markets roundup here](https://asset.wsj.net/dynamic-insets/charts/cdc_e9eaa35f6d4, Headline: Seagen, Union Pacific rise; Range Resources, Tegna fall, source:Associated Press, The, summary: No summary, Headline: NEW YORK CLOSE: US stocks end higher rising after worst week of 2023, source:Alliance News, summary: No summary, Headline: Health Care Down on Deal Doubts -- Health Care Roundup, source:MarketWatch, summary: Health-care companies ticked down amid doubts about the outlook for deal activity. Drug giant Pfizer is in talks to acquire oncology-oriented biotech company..., Headline: Fisker, Zillow, Seagen, Union Pacific stocks rise after back-to-back losses for S&P 500, source:Yahoo, summary: Yahoo Finance Live’s Brad Smith discusses Monday's trending tickers, including Fisker, Zillow, Seagen, and Union Pacific., Headline: Start Putting Together Your Shopping List For Beaten-Down Tech Stocks, source:SeekingAlpha, summary: Put together a stock shopping list. You have time to understand the stocks you are investing in., Headline: The 20 worst U.S. stocks in February: the biggest loser dropped 35%, source:MarketWatch, summary: No summary",SGEN
75,2023-02-28,"Headline: Morgan Stanley Reaffirms Their Buy Rating on Seagen (SGEN), source:TipRanks, summary: No summary, Headline: Seagen price target raised to $210 from $180 at Oppenheimer, source:Thefly.com, summary: No summary, Headline: Seagen CFO sells $3.65M in common stock, source:Thefly.com, summary: No summary, Headline: Guggenheim Sticks to Its Buy Rating for Seagen (SGEN), source:TipRanks, summary: No summary, Headline: Pfizer favored over Merck for Seagen acquisition: SVB analyst, source:Yahoo, summary: Seagen is once again an acquisition target this year, pursued by yet another partner, Pfizer. Last year, a deal with Merck fell through over price disagreements., Headline: Lightning Round: Pfizer's got a weaker pipeline than we thought, source:CNBC, summary: Mad Money host Jim Cramer weighs in on all manner of stocks, including Eli Lilly, Abbott Labs, Analog Devices, Pfizer, ADMA Biologics, Freyr Battery SA and Barrick Gold., Headline: This ETF Has 67% Upside Potential, According to Analysts, source:TipRanks, summary: No summary",SGEN
76,2023-03-01,"Headline: Pfizer/BioNTech seek U.S. emergency nod for updated COVID booster in kids, source:Seeking Alpha, summary: No summary, Headline: Estimating The Fair Value Of Seagen Inc. (NASDAQ:SGEN), source:Yahoo, summary: Key Insights Using the 2 Stage Free Cash Flow to Equity, Seagen fair value estimate is US$178 Current share price of..., Headline: Bears control the stock market for now, but these takeover plays can keep the bulls satisfied, source:MarketWatch, summary: No summary, Headline: Analysts` Opinions Are Mixed on These Healthcare Stocks: Jazz Pharmaceuticals (JAZZ), Seagen (SGEN) and IVERIC bio (ISEE), source:TipRanks, summary: No summary",SGEN
77,2023-03-02,"Headline: SVB says Pfizer could create value for holders with Seagen bid up to $253, source:Thefly.com, summary: No summary",SGEN
78,2023-03-05,"Headline: Pfizer: Crucial Moment For Buyers At Its 52-Week Low, source:SeekingAlpha, summary: Investors stampeded out of Pfizer stock this week, driving it to a 52-week low. Read more to see why we rate PFE stock a strong buy., Headline: The five-year returns have been impressive for Seagen (NASDAQ:SGEN) shareholders despite underlying losses increasing, source:Yahoo, summary: The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put..., Headline: Why Seagen is a top acquisition target?, source:Seeking Alpha, summary: No summary, Headline: Seagen seesaws amid report that Pfizer only bidder for the cancer-focused biotech, source:Seeking Alpha, summary: No summary, Headline: What To Expect From Pfizer In The Post-COVID-19 Era, source:SeekingAlpha, summary: In Q4 2022, the company's revenue was $24.29 billion, up 1.9% from the last three months of 2021, despite a significant decrease in people's desire to vaccinate against COVID-19.",SGEN
79,2023-03-06,"Headline: Seagen price target raised to $185 from $178 at Needham, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Seagen (SGEN) and BioVie (BIVI), source:TipRanks, summary: No summary, Headline: Health Care Down on Mixed Views For Deal Activity -- Health Care Roundup, source:MarketWatch, summary: Health-care companies ticked down as traders hedged their bets on the outlook for deal activity. Seagen's novel antibody drug conjugate cancer drugs have..., Headline: Seagen’s Cancer Therapy Is Making It a Takeover Target, source:Yahoo, summary: The unprofitable biotech that pioneered novel cancer agents has caught the attention of the world’s largest drugmakers.",SGEN
80,2023-03-07,"Headline: Wall Street Breakfast: Bigger Hikes Ahead?, source:SeekingAlpha, summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.",SGEN
81,2023-03-09,"Headline: Seagen, Astellas says China`s NMPA accepts BLA for enfortumab vedtoin, source:Thefly.com, summary: No summary, Headline: Analysts Conflicted on These Healthcare Names: Seagen (SGEN) and Bright Health Group (BHG), source:TipRanks, summary: No summary, Headline: Astellas and Seagen Announce China’s National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer, source:Business Wire, summary: No summary, Headline: Astellas and Seagen Announce China's National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer, source:Yahoo, summary: Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., ""Astellas"") and Seagen Inc. (Nasdaq: SGEN) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer (la/mUC) who received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy.",SGEN
82,2023-03-10,"Headline: Astellas, Seagen`s bladder cancer therapy gets review in China, source:Seeking Alpha, summary: No summary, Headline: Astellas and Seagen tout approval of bladder cancer treatment in China, source:Alliance News, summary: No summary",SGEN
83,2023-03-11,"Headline: The stock market is telling you loud and clear: Now is not the time to fight the Fed or stand up to the bears., source:MarketWatch, summary: No summary",SGEN
84,2023-03-12,"Headline: Seagen downgraded to Hold from Buy at Needham, source:Thefly.com, summary: No summary, Headline: Seagen downgraded to Market Perform from Strong Buy at Raymond James, source:Thefly.com, summary: No summary, Headline: Needham downgrades Seagen, says competing bid unlikely, source:Thefly.com, summary: No summary, Headline: Pfizer`s $43 billion bid for Seagen aims to broaden  company`s cancer portfolio, source:MarketWatch, summary: No summary, Headline: Pfizer CEO doesn`t see antitrust as stumbling block for Seagen acquisition, source:Seeking Alpha, summary: No summary, Headline: What You Missed On Wall Street On Monday, source:Thefly.com, summary: No summary",SGEN
85,2023-03-13,"Headline: These Stocks Are Moving the Most Today: First Republic, Provention Bio, Roku, Illumina, Boeing, and More Market Movers, source:MarketWatch, summary: First Republic shares are sinking Monday even as it received funding from JPMorgan Chase and the Federal Reserve, Provention Bio soars after agreeing to be..., Headline: Pfizer to acquire Seagen for $229 per share in cash, source:Thefly.com, summary: No summary, Headline: Pfizer to purchase Seagen in $43 billion all-cash deal, cancer biotech`s stock pops 20%, source:MarketWatch, summary: No summary, Headline: Today`s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday, source:InvestorPlace, summary: No summary, Headline: Pfizer to purchase Seagen in $43 billion all-cash deal, cancer biotech’s stock pops 20%, source:MarketWatch, summary: Pfizer Inc. plans to acquire cancer biotechnology company Seagen Inc. in a deal with a $43 billion enterprise value, the companies announced Monday morning...., Headline: Pfizer buys Seagen for $43B, boosts access to cancer drugs, source:Associated Press, The, summary: No summary, Headline: Pfizer Rolls the Dice on Seagen in $43 Billion Deal. The Risks It Faces., source:MarketWatch, summary: The pharmaceutical company will pay $229 a share in cash. The offer is based on the biotech firm hitting $10 billion in revenue in 2030., Headline: S&P 500 Futures Climb in Premarket Trading; First Republic Bank, Western Alliance Bancorp Lag, source:MarketWatch, summary: With U.S. stock markets set to open in two hours, (SGEN) was up 19.3% in pre-market trading, and (ILMN) was up 7.2%. (XM), (PODD), and (BILL) were all..., Headline: Pfizer Snaps Up Seagen for $43B, source:TipRanks, summary: No summary, Headline: Seagen downgraded to In Line from Outperform at Evercore ISI, source:Thefly.com, summary: No summary, Headline: MSTR, HIVE and FSM among pre market gainers, source:Seeking Alpha, summary: No summary, Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: No summary, Headline: Stocks making the biggest moves premarket: Illumina, First Republic, Seagen and more, source:CNBC, summary: Bank lenders saw major losses in early morning trading, stinging from the closure of Silicon Valley Bank and Signature Bank. , Headline: Merck downgraded at Wells Fargo on valuation, source:Seeking Alpha, summary: No summary, Headline: Seagen downgraded to Market Perform from Outperform at BMO Capital, source:Thefly.com, summary: No summary, Headline: BMO Capital downgrades Seagen (SGEN) to a Hold, source:TipRanks, summary: No summary, Headline: TOP NEWS: Pfizer buys biotechnology firm Seagen for USD43 billion, source:Alliance News, summary: No summary, Headline: Provention, Caleminder top healthcare gainers; Cingulate, iCAD among losers, source:Seeking Alpha, summary: No summary, Headline: SGEN Stock Alert: Pfizer Buys Seagen in GIANT $43 Billion Deal, source:InvestorPlace, summary: No summary, Headline: Pfizer Invests $43 Billion to Battle Cancer, source:Yahoo, summary: NEW YORK & BOTHELL, Wash., March 13, 2023--Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion. The Boards of Directors of both companies have unanimously approved the transaction., Headline: Pfizer to buy Seagen in deal valued at $43 billion , source:Reuters, summary: Pfizer Inc said on Monday it would buy Seagen Inc in a deal valued at $43 billion including debt to expand its portfolio of cancer treatments. (Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty), Headline: Why did Moderna stock go up today? Street upgrade, source:Seeking Alpha, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: JMP Securities downgrades Seagen (SGEN) to a Hold, source:TipRanks, summary: No summary, Headline: Seagen has one of the greatest technologies to battle cancer: Pfizer CEO on acquisition, source:CNBC, summary: Albert Bourla, Pfizer CEO, joins 'Squawk on the Street' to discuss his thoughts on the company buying Seagen., Headline: Stocks making the biggest moves midday: First Republic Bank, Moderna, Newmont, Illumina and more, source:CNBC, summary: These are the stocks posting the largest moves midday., Headline: Pfizer Buys Seagen - Why This Deal May Not Please Shareholders, source:SeekingAlpha, summary: Pfizer (PFE) to acquire Seagen (SGEN) for ~$43 billion. Read this article to know why I think that this deal may not please the shareholders., Headline: Pfizer CEO says it will be able to deliver Seagen's cancer therapy at a scale not seen before with $43 billion deal , source:CNBC, summary: Pfizer CEO Albert Bourla said it will deliver Seagen's cancer therapy to the world at a scale that hasn't been seen before with its $43 billion acquisition. , Headline: Pfizer Agrees to Buy Seagen for $43 Billion, source:Yahoo, summary: The drugmaker would pay $229 a share in cash for the biotech company and its pioneering cancer treatments., Headline: Pfizer aiming to acquire Seagen in $43 billion deal, source:Yahoo, summary: Yahoo Finance Live’s Julie Hyman discusses reports that Pfizer is aiming to acquire Seagen in a $43 billion deal., Headline: Pfizer ‘to battle cancer’ with Seagen merger, CEO  Albert Bourla says, source:Yahoo, summary: Pfizer CEO Albert Bourla joins Yahoo Finance Live’s Julie Hyman to discuss the acquisition of biotechnology company Seagen, the next generation of cancer breakthrough treatments, and the outlook for profit growth., Headline: NEW YORK MARKET CLOSE: Biden's reassurance fails to stop banks falling, source:Alliance News, summary: No summary, Headline: KeyCorp, Philips 66 fall; Seagen, Insulet rise, source:Associated Press, The, summary: No summary, Headline: Pfizer looks past COVID with $43 billion deal for cancer drug maker Seagen, source:Reuters, summary: Pfizer Inc on Monday struck a $43 billion deal to acquire Seagen Inc and its targeted cancer therapies as it braces for a steep fall in COVID-19 sales and generic competition for some top-selling drugs., Headline: Pfizer Overpays for Seagen, but Who’s Counting, source:Yahoo, summary: Acquiring top biotech assets as other big pharmaceutical companies face a patent cliff was bound to be expensive., Headline: CNBC Daily Open: The bank rout continues. The Fed might still raise rates anyway, source:CNBC, summary: Bank stocks had a very rough Monday in the aftermath of Silicon Valley Bank’s implosion. The 2-year Treasury yield plummeted. , Headline: Evercore ISI Group Downgrades Seattle Genetics (SGEN), source:Fintel, summary: nan, Headline: What Pfizer Is Getting From The Seagen Acquisition, source:SeekingAlpha, summary: Pfizer will acquire Seagen for $43 billion or $229 per share. Click here to read what PFE stock will get from acquiring SGEN stock., Headline: Barclays Sticks to Its Hold Rating for Seagen (SGEN), source:TipRanks, summary: No summary, Headline: CNBC Daily Open: Banks got hammered by SVB's collapse. But the Fed might still raise rates , source:CNBC, summary: Bank stocks had a very rough Monday in the aftermath of Silicon Valley Bank’s implosion. The 2-year Treasury yield plummeted. , Headline: Seagen downgraded to Market Perform from Outperform at JMP Securities, source:Thefly.com, summary: No summary",SGEN
86,2023-03-14,"Headline: Corrections & Amplifications, source:Yahoo, summary: CORRECTIONS The Nord Stream and Nord Stream 2 pipelines run between the western shores of Russia and the northern coast of Germany. A World News article on Saturday about September’s sabotage of the natural-gas pipelines incorrectly said they run from Russia’s eastern shores., Headline: Seagen price target raised to $228 from $145 at Barclays, source:Thefly.com, summary: No summary, Headline: Seagen (NASDAQ:SGEN) Stock Gained 54% YTD. Can Its Momentum Continue?, source:TipRanks, summary: No summary, Headline: Morgan Stanley Sticks to Its Buy Rating for Seagen (SGEN), source:TipRanks, summary: No summary, Headline: Seagen price target raised to $229 from $210 at Oppenheimer, source:Thefly.com, summary: No summary, Headline: RBC Capital Remains a Buy on Seagen (SGEN), source:TipRanks, summary: No summary, Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Seagen (SGEN), Sanofi (OtherSNYNF) and Amylyx Pharmaceuticals Inc (AMLX), source:TipRanks, summary: No summary, Headline: Seagen price target raised to $229 from $141 at SVB Securities, source:Thefly.com, summary: No summary, Headline: GLOBAL BROKER RATINGS: Numis cuts Seagen; SocGen cuts Saint-Gobain, source:Alliance News, summary: No summary, Headline: Seagen price target raised to $229 from $155 at RBC Capital, source:Thefly.com, summary: No summary, Headline: Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: No summary, Headline: Strength Seen in Seattle Genetics (SGEN): Can Its 14.5% Jump Turn into More Strength?, source:Yahoo, summary: Seattle Genetics (SGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term., Headline: JPMorgan biotech/pharma analysts to hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting, source:Yahoo, summary: BOTHELL, Wash., March 14, 2023--Seagen Inc. (Nasdaq: SGEN) today announced the presentation of 17 abstracts featuring new clinical and preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando from April 14-19, 2023. The broad range of data being presented at this year’s meeting includes research from Seagen’s approved medicines, as well as data from early-stage clinical, preclinical, and discovery research programs., Headline: BMO Capital Downgrades Seattle Genetics (SGEN), source:Fintel, summary: nan, Headline: JMP Securities Downgrades Seattle Genetics (SGEN), source:Fintel, summary: nan, Headline: Raymond James Downgrades Seattle Genetics (SGEN), source:Fintel, summary: nan, Headline: Needham Downgrades Seattle Genetics (SGEN), source:Fintel, summary: nan, Headline: Seagen downgraded to Equal Weight from Overweight at Morgan Stanley, source:Thefly.com, summary: No summary",SGEN
87,2023-03-15,"Headline: GLOBAL BROKER RATINGS: HSBC says 'hold' Terna and Snam, 'buy' Enel, source:Alliance News, summary: No summary, Headline: AbbVie, Gilead, Seagen among firms fined for raising prices faster than inflation, source:Seeking Alpha, summary: No summary, Headline: Medicare identifies drug makers that will owe penalties for raising prices on 27 drugs faster than rate of inflation, source:Yahoo, summary: The Biden administration is making good on promises to help lower drug costs, though the impact is largely for Medicare patients., Headline: Lightning Round: We're not gonna recommend an stocks that are oozing big money, source:CNBC, summary: Mad Money host Jim Cramer weighs in on all manner of stocks, including Vir Biotechnology, Pfizer, Seagen and Origin Materials., Headline: Morgan Stanley Downgrades Seattle Genetics (SGEN), source:Fintel, summary: nan",SGEN
88,2023-03-16,"Headline: Today`s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday, source:InvestorPlace, summary: No summary, Headline: Stock market volatility this week has triggered a new sell signal, source:MarketWatch, summary: No summary, Headline: JPMorgan biotech/pharma analysts to hold KOL analyst/industry conference call, source:Thefly.com, summary: No summary",SGEN
89,2023-03-17,"Headline: Why Is Seattle Genetics (SGEN) Up 24.6% Since Last Earnings Report?, source:Yahoo, summary: Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues., Headline: Seagen and Newell Brands Stock See Action From Activist Investors, source:MarketWatch, summary: Activists file with the SEC on Seagan, ODP, Newell Brands, and Chinook Therapeutics, Headline: First Republic Bank, T-Mobile, Credit Suisse: Stocks That Defined the Week, source:Yahoo, summary: Wall Street’s biggest banks swooped in to rescue First Republic after a week of turmoil.  First Republic was among the banks swept up in the contagion following the recent failure of Silicon Valley Bank parent SVB Financial Corp. Banks including  JPMorgan Chase & Co. Citigroup  and  Wells Fargo  & Co., deposited a total of $30 billion in an effort to stop the spreading panic.  First Republic shares dropped 33% Friday., Headline: Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement, source:TalkMarkets, summary: No summary",SGEN
90,2023-03-20,"Headline: Seagen price target raised to $229 from $152 at Truist, source:Thefly.com, summary: No summary, Headline: Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement, source:Seeking Alpha, summary: No summary",SGEN
91,2023-03-22,"Headline: Moderna: Now`s Your Chance (Rating Upgrade), source:Seeking Alpha, summary: No summary, Headline: Moderna: Now's Your Chance (Rating Upgrade), source:SeekingAlpha, summary: Moderna stock potential is overshadowed by downcast analysts' projections of three years of operating losses until 2025. Click here for our take on MRNA., Headline: Seagen (SGEN) Gets a Hold from Cowen & Co., source:TipRanks, summary: No summary",SGEN
92,2023-03-23,"Headline: We're Not Worried About Seagen's (NASDAQ:SGEN) Cash Burn, source:Yahoo, summary: Just because a business does not make any money, does not mean that the stock will go down. For example, although..., Headline: CRISPR Therapeutics AG (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?, source:Yahoo, summary: CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",SGEN
93,2023-03-24,"Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Seagen (SGEN), Aptose Biosciences (APTO) and GeoVax Labs (GOVX), source:TipRanks, summary: No summary, Headline: Seagen downgraded to Hold from Buy at Berenberg, source:Thefly.com, summary: No summary, Headline: Why Is Repligen (RGEN) Down 11.4% Since Last Earnings Report?, source:Yahoo, summary: Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",SGEN
94,2023-03-27,"Headline: 3 Low P/E Stocks That Are Bound to Rebound This Year, source:InvestorPlace, summary: No summary, Headline: A Seagen Inc. (NASDAQ:SGEN) insider lowered their holding by 16% earlier this year, source:Yahoo, summary: Viewing insider transactions for Seagen Inc.'s ( NASDAQ:SGEN ) over the last year, we see that insiders were net..., Headline: Notable Tuesday Option Activity: SGEN, HUM, GOOGL, source:Stock Options Channel, summary: No summary",SGEN
95,2023-03-29,"Headline: Axsome (AXSM) Down 9.8% Since Last Earnings Report: Can It Rebound?, source:Yahoo, summary: Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",SGEN
96,2023-03-30,"Headline: Pfizer-backed Pyxis hits 52-week high to cross $200M market cap, source:Seeking Alpha, summary: No summary, Headline: Why Is Iovance Biotherapeutics (IOVA) Down 9.2% Since Last Earnings Report?, source:Yahoo, summary: Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",SGEN
97,2023-03-31,"Headline: Amicus Therapeutics (FOLD) Down 14% Since Last Earnings Report: Can It Rebound?, source:Yahoo, summary: Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",SGEN
98,2023-04-02,"Headline: Seagen/Pfizer deal spread becoming increasingly attractive, analyst says, source:Seeking Alpha, summary: No summary",SGEN
99,2023-04-03,"Headline: Seagen, Astellas announce FDA grants Padcev with Keytruda accelerated approval, source:Thefly.com, summary: No summary, Headline: Amazon-iRobot And 16 Other Opportunities In Merger Arbitrage Space, source:SeekingAlpha, summary: Merger arbitrage spreads are wide. There are plenty of opportunities with spreads of up to 118%., Headline: FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer, source:Yahoo, summary: BOTHELL, Wash. & TOKYO, April 03, 2023--Seagen Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE:4503) today announced the U.S. Food and Drug Administration (FDA) has granted PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) accelerated approval in the U.S. as a combination therapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) who are not eligible to receive cisplatin-containing chemotherapy. This indication is approved under ac, Headline: US FDA grants accelerated approval for Padcev with Keytruda for cancer, source:Alliance News, summary: No summary",SGEN
100,2023-04-04,"Headline: Seagen (SGEN) Gets a Hold from Morgan Stanley, source:TipRanks, summary: No summary, Headline: Padcev combo approval should alleviate concerns on Seagen deal, says BofA, source:Thefly.com, summary: No summary, Headline: Tracking Baker Brothers Portfolio - Q4 2022 Update, source:SeekingAlpha, summary: Baker Brothersâ 13F portfolio value increased from $15.27B to $16.65B this quarter. Click here to see the Q4 2022 update on the portfolio.",SGEN
101,2023-04-06,"Headline: Is Pfizer Stock a Buy, Sell or Hold? Here`s My Call., source:InvestorPlace, summary: No summary, Headline: Estimating The Intrinsic Value Of Seagen Inc. (NASDAQ:SGEN), source:Yahoo, summary: Key Insights Seagen's estimated fair value is US$194 based on 2 Stage Free Cash Flow to Equity Seagen's US$205 share...",SGEN
102,2023-04-07,"Headline: RBC Capital Sticks to Their Buy Rating for Seagen (SGEN), source:TipRanks, summary: No summary, Headline: Seagen to Report First Quarter 2023 Financial Results on April 27, 2023, source:Yahoo, summary: BOTHELL, Wash., April 07, 2023--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its first quarter 2023 financial results on Thursday, April 27, 2023.",SGEN
103,2023-04-09,"Headline: Pfizer: Trying To Acquire Growth, source:SeekingAlpha, summary: Pfizer has used the vaccine boom and related profits from the pandemic to pursue a flurry of deals. Click here to see our take on PFE stock.",SGEN
104,2023-04-11,"Headline: Investors in Seagen (NASDAQ:SGEN) have made a incredible return of 307% over the past five years, source:Yahoo, summary: Long term investing can be life changing when you buy and hold the truly great businesses. While not every stock...",SGEN
105,2023-04-17,"Headline: Seagen Inc.'s (NASDAQ:SGEN) Business Is Trailing The Industry But Its Shares Aren't, source:Yahoo, summary: You may think that with a price-to-sales (or ""P/S"") ratio of 19.6x Seagen Inc. ( NASDAQ:SGEN ) is a stock to avoid..., Headline: Pfizer Vs. AstraZeneca: Which Is Better For Long-Term Investors?, source:SeekingAlpha, summary: nan",SGEN
106,2023-04-18,"Headline: Pfizer: A Deep Value Play for the Long Term, source:GuruFocus, summary: No summary, Headline: Buy Seagen Now For An Attractive M&A Arbitrage Opportunity, source:SeekingAlpha, summary: nan, Headline: MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting, source:Business Wire, summary: No summary",SGEN
107,2023-04-19,"Headline: TD Cowen merger specialist to hold an analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Unusual Put Option Trade in Seattle Genetics (SGEN)  Worth $260.00K, source:Fintel, summary: nan",SGEN
108,2023-04-20,"Headline: Biopharma Deals Are Hot. There’s More to Come—and These Stocks Can Benefit., source:MarketWatch, summary: In the first quarter of this year, total healthcare and life sciences M&A in the U.S. was about $71 billion, according to KPMG.",SGEN
109,2023-04-23,"Headline: What is behind biotech M&A resurgence?, source:Seeking Alpha, summary: No summary",SGEN
110,2023-04-24,"Headline: 3 Low P/E Stocks That Will Double in One Year, source:InvestorPlace, summary: No summary, Headline: Second Quarter Outlook For Biotech Stocks, source:SeekingAlpha, summary: nan, Headline: We're Interested To See How Seagen (NASDAQ:SGEN) Uses Its Cash Hoard To Grow, source:Yahoo, summary: Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...",SGEN
111,2023-04-25,"Headline: Second Quarter Outlook For Biotech Stocks, source:TalkMarkets, summary: No summary, Headline: Repligen (RGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release, source:Yahoo, summary: Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",SGEN
112,2023-04-26,"Headline: Seagen says bladder cancer, Padcev data to highlight ASCO presentations, source:Thefly.com, summary: No summary, Headline: Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting, source:Yahoo, summary: BOTHELL, Wash., April 26, 2023--Seagen Inc. (Nasdaq: SGEN) today announced the presentation of 17 abstracts at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023, in Chicago. Data will be presented across Seagen's portfolio of approved medicines and pipeline agents in a range of cancer types and in earlier lines of therapy., Headline: GLOBAL BRIEFING: Samsung posts weakest profit in 14 years in Q1, source:Alliance News, summary: No summary, Headline: Seagen (SGEN) Receives a Hold from Berenberg Bank, source:TipRanks, summary: No summary, Headline: JMP Securities Sticks to Their Hold Rating for Seagen (SGEN), source:TipRanks, summary: No summary",SGEN
113,2023-04-27,"Headline: Seagen reports Q1 EPS (93c), consensus (82c), source:Thefly.com, summary: No summary, Headline: Seattle Genetics: Q1 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Seagen Reports First Quarter 2023 Financial Results, source:Yahoo, summary: BOTHELL, Wash., April 27, 2023--Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the first quarter ended March 31, 2023. The Company also highlighted performance across its approved product portfolio, development accomplishments, and progress across its differentiated oncology pipeline of innovative ADCs and targeted therapies., Headline: Seattle Genetics (SGEN) Reports Q1 Loss, Lags Revenue Estimates, source:Yahoo, summary: Seattle Genetics (SGEN) delivered earnings and revenue surprises of -13.41% and 0.23%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?, Headline: Seattle Genetics (SGEN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates, source:Yahoo, summary: While the top- and bottom-line numbers for Seattle Genetics (SGEN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values., Headline: Noteworthy Friday Option Activity: SGEN, CTLT, PTON, source:Stock Options Channel, summary: No summary",SGEN
114,2023-04-28,"Headline: Seagen price target raised to $229 from $157 at Stifel, source:Thefly.com, summary: No summary",SGEN
115,2023-04-29,"Headline: 16% of this Seagen Inc. (NASDAQ:SGEN) insider's holdings were sold in the last year, source:Yahoo, summary: Looking at Seagen Inc.'s ( NASDAQ:SGEN ) insider transactions over the last year, we can see that insiders were net..., Headline: 7 High-Yield Dividend Stocks to Buy and Hold Forever, source:InvestorPlace, summary: No summary",SGEN
116,2023-05-01,"Headline: RBC Capital Sticks to Its Buy Rating for Seagen (SGEN), source:TipRanks, summary: No summary, Headline: Seagen (SGEN) Gets a Hold from SVB Securities, source:TipRanks, summary: No summary",SGEN
117,2023-05-02,"Headline: Pfizer tops Q1 2023 forecasts as COVID franchise outperforms, source:Seeking Alpha, summary: No summary, Headline: Pfizer tops Q1 forecasts; vaccine sales slide as expected, source:Associated Press, The, summary: No summary, Headline: MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy, source:Business Wire, summary: No summary, Headline: Stifel Nicolaus Sticks to Their Hold Rating for Seagen (SGEN), source:TipRanks, summary: No summary, Headline: Pfizer Will Shift Focus to Dividends and Share Buybacks, Execs Say, source:MarketWatch, summary: The drugmaker has been on an M&A hot streak over the past couple of years.",SGEN
118,2023-05-03,"Headline: PRESS: Pfizer to begin selling Haleon interest within months - FT, source:Alliance News, summary: No summary, Headline: LONDON MARKET CLOSE: FTSE 100 in the green ahead of Fed rate decision, source:Alliance News, summary: No summary",SGEN
119,2023-05-07,"Headline: Noteworthy Monday Option Activity: SGEN, IRBT, ABNB, source:Stock Options Channel, summary: No summary",SGEN
120,2023-05-08,"Headline: Estimating The Intrinsic Value Of Seagen Inc. (NASDAQ:SGEN), source:Yahoo, summary: Key Insights Using the 2 Stage Free Cash Flow to Equity, Seagen fair value estimate is US$193 With US$200 share price...",SGEN
121,2023-05-10,"Headline: Oppenheimer upgrades Corbus Pharmaceuticals to Outperform with $22 target, source:Thefly.com, summary: No summary",SGEN
122,2023-05-11,"Headline: TOP NEWS: GSK intends to sell up to 240 million shares in Haleon, source:Alliance News, summary: No summary, Headline: Pfizer`s COVID-19 profits supporting development of cancer therapies - Reuters, source:Seeking Alpha, summary: No summary",SGEN
123,2023-05-12,"Headline: Seagen Inc. (NASDAQ:SGEN) is largely controlled by institutional shareholders who own 65% of the company, source:Yahoo, summary: Key Insights Significantly high institutional ownership implies Seagen's stock price is sensitive to their trading...",SGEN
124,2023-05-15,"Headline: Pfizer, Seagen filed with FTC, DOJ on Friday in regards to $43B deal, source:Seeking Alpha, summary: No summary, Headline: Pfizer launches debt offering for Seagen acquisition, source:Seeking Alpha, summary: No summary, Headline: FTC suit against Horizon deal may have chilling effect on biotech M&A, source:Seeking Alpha, summary: No summary, Headline: Video: Nasdaq 100 Movers: SGEN, AMD, source:Market News Video, summary: No summary, Headline: Noteworthy Tuesday Option Activity: SGEN, SBGI, MSTR, source:Stock Options Channel, summary: No summary, Headline: Horizon Therapeutics plunges as FTC lawsuit increases risk to Amgen deal (update), source:Seeking Alpha, summary: No summary",SGEN
125,2023-05-16,"Headline: Seagen, impacted by FTC Amgen/Horizon suit, closes down 6%, source:Seeking Alpha, summary: No summary, Headline: Seagen (SGEN) Receives a Hold from Berenberg Bank, source:TipRanks, summary: No summary, Headline: Horizon Therapeutics plunges as potential FTC lawsuit increases risk to Amgen deal, source:Seeking Alpha, summary: No summary, Headline: TIGR, APLS and LMFA among pre-market losers, source:Seeking Alpha, summary: No summary, Headline: What You Missed On Wall Street On Tuesday, source:Thefly.com, summary: No summary, Headline: Seagen, Prometheus Biosciences fall amid news of FTC planned block of Horizon/Amgen deal, source:Seeking Alpha, summary: No summary, Headline: Stocks making the biggest moves premarket: Home Depot, Capital One, Dish Network & more, source:CNBC, summary: These are the stocks posting the largest moves in premarket trading. , Headline: Horizon Therapeutics plunges as potential FTC lawsuit increases risk to Amgen deal (update), source:Seeking Alpha, summary: No summary, Headline: Seagen (SGEN) Stock Falls 6% After Director Sells Shares, source:InvestorPlace, summary: No summary, Headline: GILD Stock Price Predictions: Is Gilead Sciences Really Worth $100?, source:InvestorPlace, summary: No summary, Headline: Why Is Guardforce AI (GFAI) Stock Up Today?, source:InvestorPlace, summary: No summary, Headline: GDC Stock Alert: Why Is GD Culture Group Up 106% Today?, source:InvestorPlace, summary: No summary, Headline: Prometheus, Seagen slip after FTC sues to block Horizon acquisition, source:Thefly.com, summary: No summary, Headline: Seagen likely to stay `distanced` from deal price after FTC action, says Stifel, source:Thefly.com, summary: No summary, Headline: Stocks making the biggest moves midday: Horizon Therapeutics, Capital One, RH, Home Depot and more , source:CNBC, summary: These are the stocks posting the largest moves midday., Headline: Seagen (NASDAQ:SGEN) shareholders have earned a 29% CAGR over the last five years, source:Yahoo, summary: The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company..., Headline: FTC sues to block Amgen's $28B acquisition of Horizon Therapeutics, source:Yahoo, summary: The regulator said its decision ""sends a clear signal to the market"" about consolidation in the pharmaceutical market, though analysts expect the deal will still go through despite delays., Headline: Pfizer plans to raise $31 bln from debt offering to finance Seagen takeover, source:Reuters, summary: Pfizer Inc said on Tuesday it plans to raise $31 billion from a debt offering to finance its proposed acquisition of Seagen Inc. (Reporting by Kanjyik Ghosh in Bengaluru), Headline: Unusual Put Option Trade in Seagen (SGEN)  Worth $5,030.00K, source:Fintel, summary: nan, Headline: Pfizer plans $31 billion debt offering to fund Seagen takeover, source:Reuters, summary: Pfizer Inc said on Tuesday it plans to raise $31 billion from a debt offering to finance its proposed acquisition of Seagen Inc.",SGEN
126,2023-05-17,"Headline: Debt Ceiling Negotiations Turn a Corner. Why The Risk Isn’t Over Yet., source:MarketWatch, summary: Still no debt-ceiling deal as Biden shortens G-7 trip, UBS takes $35 billion gain from Credit Suisse takeover, Musk hints at two new vehicles and starts..., Headline: Pfizer Prices $31 Billion Debt Offering to Fund Seagen Acquisition, source:MarketWatch, summary: Pfizer's acquisition of cancer-focused biotech Seagen, announced in March, would be its biggest since 2009. The deal faces risks., Headline: Interesting SGEN Put And Call Options For August 18th, source:Stock Options Channel, summary: No summary, Headline: Pfizer to raise $31 billion in debt offering to fund Seagen acquisition, SEC filing shows, source:CNBC, summary: The debt offering by Pfizer to buy cancer drug maker Seagen comes as Apple, Merck and T-Mobile tap the U.S. bond market ahead of the debt ceiling standoff. , Headline: Pfizer to raise $31 billion for Seagen takeover in largest debt offering, source:Reuters, summary: Pfizer Inc is planning to raise $31 billion through its largest debt offering to finance its proposed acquisition of Seagen Inc, the drugmaker said late on Tuesday., Headline: Top 5 1st Quarter Trades of INTERNATIONAL BIOTECHNOLOGY TRUST PLC, source:GuruFocus, summary: No summary",SGEN
127,2023-05-18,"Headline: Pfizer: Ridiculous Selloff To A 2-Year Low, source:SeekingAlpha, summary: Pfizer hits a two-year low on COVID vaccines revenue pessimism, but valuation is attractive as sellers rushed out. Click here to read more on PFE stock., Headline: This Insider Just Sold Shares of Seagen Inc, source:GuruFocus, summary: No summary",SGEN
128,2023-05-19,"Headline: Should Investors Worry About Seagen Inc`s Insider Sells?, source:GuruFocus, summary: No summary",SGEN
129,2023-05-20,"Headline: Should Investors Worry About Seagen Inc's Insider Sells?, source:GuruFocus, summary: No summary",SGEN
130,2023-05-21,"Headline: Seagen Larger Than S&P 500 Component GE HealthCare Technologies, source:The Online Investor, summary: No summary",SGEN
131,2023-05-23,"Headline: SGEN, ACAD & BMEA Drove Baker Brothers Advisors' Q1 Returns as ASND and HZNP Were Culled, source:Fintel, summary: nan, Headline: 10 Health Care Stocks Whale Activity In Today's Session, source:Benzinga, summary: No summary, Headline: Notable Wednesday Option Activity: SGEN, RL, CRWD, source:Stock Options Channel, summary: No summary",SGEN
132,2023-05-25,"Headline: We're Not Worried About Seagen's (NASDAQ:SGEN) Cash Burn, source:Yahoo, summary: We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining..., Headline: Catalyst watch: C3.ai and Salesforce earnings, Knife River debut, Kenvue ratings & Faraday Future event, source:Seeking Alpha, summary: No summary",SGEN
133,2023-05-26,"Headline: Global company events calendar - next 7 days, source:Alliance News, summary: No summary",SGEN
134,2023-05-29,"Headline: Pfizer: Not Quite Dead Money Walking, source:SeekingAlpha, summary: Pfizer's success in the COVID-19 pandemic has unfortunately become a double-edged sword. Read more to see my analysis of PFE stock and why it is a Buy., Headline: Seagen shareholders approve acquisition by Pfizer, source:Thefly.com, summary: No summary, Headline: Seagen shareholders OK acquisition by Pfizer, source:Seeking Alpha, summary: No summary",SGEN
135,2023-05-30,"Headline: Top Merger Stocks Held By Fund Managers, Mid-Q2 2023, source:SeekingAlpha, summary: Merger arbitrage in mid-2023 faces regulatory hurdles, with agencies attempting to block deals across industries. Read more here., Headline: Seagen Shareholders Approve Pfizer's Acquisition Deal, source:MarketWatch, summary: By Sabela Ojea Seagen said Tuesday its shareholders voted in favor of Pfizer buying the company for $43 billion. The biotechnology cancer specialist..., Headline: Seagen Stockholders Approve Acquisition by Pfizer, source:Yahoo, summary: BOTHELL, Wash., May 30, 2023--Following a special meeting of its stockholders, Seagen Inc. (Nasdaq: SGEN) today announced that its stockholders voted to approve a proposal to adopt the previously announced merger agreement under which Pfizer will acquire Seagen for $229 per share in cash. More than 99% of the shares voted at the meeting, representing approximately 88% of the shares of Seagen common stock issued and outstanding as of the record date for the special meeting, were voted in favor of, Headline: GLOBAL BRIEFING: US debt bill clears first hurdle before vote, source:Alliance News, summary: No summary",SGEN
136,2023-06-01,"Headline: Tracking Baker Brothers Portfolio - Q1 2023 Update, source:SeekingAlpha, summary: Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B. Click here to read the portfolio's full Q1 2023 update., Headline: Pfizer (NYSE:PFE) Secures FDA Approval for RSA Vaccine, source:TipRanks, summary: No summary, Headline: Pfizer Stock (NYSE:PFE) – New FDA Approval Could Stop Its Drop, source:TipRanks, summary: No summary",SGEN
137,2023-06-02,"Headline: 3 Undervalued Biotech Stocks to Buy Before They Blast Off, source:InvestorPlace, summary: No summary",SGEN
138,2023-06-04,"Headline: Wall Street Breakfast: The Week Ahead, source:SeekingAlpha, summary: Investors head into next week with the debt ceiling crisis resolved for the near term.",SGEN
139,2023-06-06,"Headline: Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ultragenyx Pharmaceutical (RARE), Seagen (SGEN) and Moderna (MRNA), source:TipRanks, summary: No summary, Headline: Profit From The Pfizer Takeover Of Seagen, source:SeekingAlpha, summary: Pfizer is set to acquire Seagen for $43 billion, with the deal expected to close later this year or in early 2024, subject to regulatory approvals. Click here for a detailed analysis.",SGEN
140,2023-06-07,"Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Seagen (SGEN), Keros Therapeutics (KROS) and Adaptimmune Therapeutics (ADAP), source:TipRanks, summary: No summary, Headline: If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,800 Today, source:Benzinga, summary: No summary",SGEN
141,2023-06-08,"Headline: Seagen gains as antitrust deadline for Pfizer purchase nears on Monday, source:Seeking Alpha, summary: No summary, Headline: Catalyst watch: AI talk from Salesforce and AMD, Shell event and Oracle earnings, source:Seeking Alpha, summary: No summary",SGEN
142,2023-06-10,"Headline: 5 Relatively Safe And Cheap Dividend Stocks To Invest In - June 2023, source:SeekingAlpha, summary: We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges. Read more here.",SGEN
143,2023-06-12,"Headline: Interesting SGEN Put And Call Options For September 2024, source:Stock Options Channel, summary: No summary",SGEN
144,2023-06-13,"Headline: Seagen announces updated efficacy, safety results from Part C of Adcetris study, source:Thefly.com, summary: No summary, Headline: Seagen posts 93% complete remission for lymphoma therapy in Phase 2 trial, source:Seeking Alpha, summary: No summary, Headline: Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL), source:Yahoo, summary: BOTHELL, Wash., June 13, 2023--Seagen Inc. (NASDAQ: SGEN) today announced updated efficacy and safety results from Part C of a phase 2 single-arm trial (SGN35-027) evaluating the antibody-drug conjugate ADCETRIS® (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (AN+AD) for the frontline treatment of patients with early-stage classical Hodgkin lymphoma (cHL). Data results will be presented at the 17th International, Headline: Seagen Posts Impressive Phase 2 Data in Hodgkin Lymphoma, source:TipRanks, summary: No summary, Headline: Seagen's Adcetris/Immunotherapy Combo Achieves 98% Overall Response Rate in Early-Stage Lymphoma Setting, source:Benzinga, summary: No summary, Headline: Pfizer: Deeper Value Found Amidst Diversified Pipelines, source:SeekingAlpha, summary: Pfizer presents a buying opportunity as value has deepened following weak price action due to post-pandemic revenue concerns. Read why PFE stock is a Buy., Headline: Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating, source:Benzinga, summary: No summary",SGEN
145,2023-06-14,"Headline: Pfizer pulls, refiles merger notification with FTC over Seagen deal, source:Seeking Alpha, summary: No summary, Headline: Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma, source:Yahoo, summary: BOTHELL, Wash., June 15, 2023--Seagen Inc. (NASDAQ: SGEN) today announced an update to the U.S. Prescribing Information (PI) for ADCETRIS® (brentuximab vedotin) to include six-year overall survival results from the phase 3 ECHELON-1 clinical trial of ADCETRIS plus combination chemotherapy in patients with previously untreated Stage III or IV classical Hodgkin lymphoma compared to chemotherapy alone. The statistically significant data were presented last year at the annual meetings of the America",SGEN
146,2023-06-15,"Headline: Notable Friday Option Activity: SGEN, GS, SQ, source:Stock Options Channel, summary: No summary",SGEN
147,2023-06-16,"Headline: Seagen (SGEN) Receives a Hold from SVB Securities, source:TipRanks, summary: No summary, Headline: How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities, source:TalkMarkets, summary: No summary",SGEN
148,2023-06-18,"Headline: Unlock the Potential of These 7 Cash-Flow Machines, source:InvestorPlace, summary: No summary",SGEN
149,2023-06-20,"Headline: 5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies, source:Benzinga, summary: No summary, Headline: 3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever, source:InvestorPlace, summary: No summary, Headline: Seagen reports progression free survival data from Adcetris combination study, source:Thefly.com, summary: No summary, Headline: Phase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma, source:Yahoo, summary: BOTHELL, Wash., June 20, 2023--Seagen Inc. (NASDAQ: SGEN) today announced that the clinical research cooperative German Hodgkin Study Group (GHSG) presented results showing that a phase 3 trial of ADCETRIS® in combination with chemotherapy – a regimen called BrECADD (brentuximab vedotin [ADCETRIS], etoposide, cyclophosphamide, doxorubicin [Adriamycin], dacarbazine, and dexamethasone) – met its co-primary endpoints of non-inferior efficacy and superior tolerability versus a highly efficacious yet",SGEN
150,2023-06-22,"Headline: Seagen (SGEN) Gets a Hold from SVB Securities, source:TipRanks, summary: No summary, Headline: Analysts’ Opinions Are Mixed on These Healthcare Stocks: Seagen (SGEN), Verve Therapeutics (VERV) and Cytokinetics (CYTK), source:TipRanks, summary: No summary",SGEN
151,2023-06-23,"Headline: Here's How Much You Would Have Made Owning Seagen Stock In The Last 20 Years, source:Benzinga, summary: No summary",SGEN
152,2023-06-25,"Headline: What is behind big pharma's underperformance?, source:Seeking Alpha, summary: No summary",SGEN
153,2023-06-26,"Headline: Mergers Are Down, but These 2 Sectors Are Booming, source:MarketWatch, summary: Total deal value worldwide is about $1.22 trillion year to date, according to data from London Stock Exchange Group.",SGEN
154,2023-06-29,"Headline: Seattle Genetics put volume heavy and directionally bearish, source:Thefly.com, summary: No summary",SGEN
155,2023-07-01,"Headline: The 7 Most Undervalued S&P 500 Stocks to Buy Now, source:InvestorPlace, summary: No summary",SGEN
156,2023-07-04,"Headline: Best Under-the-Radar Stocks: 3 That AI Predicts Will Soar in July, source:Yahoo, summary: Under-the-radar stocks have provided compelling returns in 2023. Indeed, the rally this year has been mostly concentrated in a few key sectors, such as technology and artificial intelligence. However, snapping up oversold stocks typically sets up portfolios for substantial long-term gains. That’s no different right now than at any other time in history. Of course, finding these hidden gems is not easy, especially when the market is flooded with hype and noise. I’ll be using Google’s Bard AI toda",SGEN
157,2023-07-06,"Headline: Investors focus on how Pfizer will spend COVID-19 windfall: GS, source:Yahoo, summary: Pharmaceutical company Pfizer is carefully calculating its next move following the windfall it experienced during the COVID-19 pandemic. Yahoo Finance Healthcare Reporter Anjalee Khemlani highlights Pfizer CEO Albert Bourla's comments on Pfizer's stock outlook and plans to return capital to investors.",SGEN
158,2023-07-07,"Headline: From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs, source:Benzinga, summary: No summary",SGEN
159,2023-07-09,"Headline: $100 Invested In Seagen 10 Years Ago Would Be Worth This Much Today, source:Benzinga, summary: No summary",SGEN
160,2023-07-10,"Headline: Pfizer: A Worthwhile Dividend Play At A Cheap Valuation, source:SeekingAlpha, summary: Pfizer is looking at the impact of a Covid/Flu combo vaccination to help drive sales. Read why PFE stock offers long-term investors an opportunity to invest., Headline: RBC Capital Keeps Their Buy Rating on Seagen (SGEN), source:TipRanks, summary: No summary, Headline: Unusual Put Option Trade in Seagen (SGEN)  Worth $1,100.00K, source:Fintel, summary: nan",SGEN
161,2023-07-11,"Headline: Microsoft’s Win in the Activision Case Could Spur a Merger Revival, source:MarketWatch, summary: Activision Blizzard, VMware, and other stocks are rallying Tuesday after a federal judge ruled that Microsoft can close on its Activision deal, Headline: Drugmakers’ deal making will plow ahead despite antitrust scrutiny, analysts say, source:MarketWatch, summary: No summary",SGEN
162,2023-07-12,"Headline: Seagen to Report Second Quarter 2023 Financial Results on August 2, 2023, source:Yahoo, summary: BOTHELL, Wash., July 12, 2023--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its second quarter 2023 financial results on Wednesday, August 2, 2023.",SGEN
163,2023-07-13,"Headline: 3 Pharma Stocks That AI is Loving in July, source:InvestorPlace, summary: No summary, Headline: Amedisys-UnitedHealth And 16 Other Opportunities In The Merger Arbitrage Space, source:SeekingAlpha, summary: In this article, you'll find a review of the most interesting setups in the merger arbitrage space. Read more here., Headline: What You Missed On Wall Street On Friday, source:Thefly.com, summary: No summary",SGEN
164,2023-07-14,"Headline: Seagen, Pfizer receive Second Request from FTC regarding merger, source:Thefly.com, summary: No summary, Headline: Seagen, Pfizer get second info request from FTC on $43B merger deal, source:Seeking Alpha, summary: No summary, Headline: Seagen, Pfizer to receive FTC second request, Dealreporter says, source:Thefly.com, summary: No summary, Headline: Seagen drops on report it will get 2nd request from FTC in Pfizer deal, source:Seeking Alpha, summary: No summary, Headline: Seagen dips on report it will get 2nd request from FTC in Pfizer deal, source:Seeking Alpha, summary: No summary, Headline: US FTC seeks additional info on Pfizer's proposed takeover of Seagen, source:Finnhub, summary: The US Federal Trade Commission
 has sought additional information and documentary material
related to Pfizer's proposed acquisition of Seagen Inc
, Seagen said on Friday.
(Reporting by Khushi...",SGEN
165,2023-07-16,"Headline: HSBC bullish on Roche, Lonza; bearish on Bristol-Myers, GSK, Moderna, source:Seeking Alpha, summary: No summary, Headline: TD Cowen analysts to hold an analyst/industry conference call, source:Thefly.com, summary: No summary",SGEN
166,2023-07-18,"Headline: SVB Securities Keeps Their Hold Rating on Seagen (SGEN), source:TipRanks, summary: No summary, Headline: How Is The Market Feeling About Seagen?, source:Benzinga, summary: No summary",SGEN
167,2023-07-19,"Headline: BAKER BROS. ADVISORS LP Acquires Significant Stake in Neoleukin Therapeutics Inc, source:GuruFocus, summary: No summary",SGEN
168,2023-07-21,"Headline: Growth Posted An Impressive First Half But Is Still Playing Catch-Up, source:SeekingAlpha, summary: The Nasdaq has provided tremendous performance so far in the first half of 2023. Click here to read more.",SGEN
169,2023-07-23,"Headline: Notable Monday Option Activity: SGEN, CALM, JKHY, source:Stock Options Channel, summary: No summary",SGEN
170,2023-07-24,"Headline: Seattle Genetics put volume heavy and directionally bearish, source:Thefly.com, summary: No summary",SGEN
171,2023-07-26,"Headline: Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?, source:Yahoo, summary: Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",SGEN
172,2023-07-27,"Headline: Seattle Genetics put volume heavy and directionally bearish, source:Thefly.com, summary: No summary",SGEN
173,2023-07-28,"Headline: Unusual Put Option Trade in Seagen (SGEN)  Worth $2,100.00K, source:Fintel, summary: nan",SGEN
174,2023-07-30,"Headline: Pfizer seen reporting sharply lower Q2 sales as COVID-19 vaccine demand wanes, source:Seeking Alpha, summary: No summary",SGEN
175,2023-08-01,"Headline: Merck Earnings Top Expectations. More M&A Could Be Next., source:MarketWatch, summary: CFO Caroline Litchfield said sales of the company’s cancer treatments and vaccines were growing and more M&A could be on the horizon., Headline: Pfizer reports 54% contraction in Q2 sales amid COVID cliff, source:Seeking Alpha, summary: No summary, Headline: Seattle Genetics Q2 2023 Earnings Preview, source:Seeking Alpha, summary: No summary, Headline: NEW YORK MARKET CLOSE: Manufacturing malaise holds Wall Street back, source:Alliance News, summary: No summary, Headline: GLOBAL BRIEFING: Fitch cuts US debt rating after debt ceiling impasse, source:Alliance News, summary: No summary",SGEN
176,2023-08-02,"Headline: Seagen reports Q2 EPS ($1.13), consensus (78c), source:Thefly.com, summary: No summary, Headline: Seattle Genetics GAAP EPS of -$1.13 misses by $0.31, revenue of $603.8M beats by $45.21M, source:Seeking Alpha, summary: No summary, Headline: Seattle Genetics: Q2 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Seattle Genetics : Q2 Earnings Snapshot, source:Finnhub, summary: BOTHELL, Wash.  — BOTHELL, Wash.  — Seattle Genetics Inc.  on Wednesday reported a loss of $211.5 million in its second quarter.
  On a per-share basis, the Bothell, Washington-based company..., Headline: Seagen posts widened loss in presumed last half-year as public firm, source:Alliance News, summary: No summary, Headline: Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum, source:Yahoo, summary: BOTHELL, Wash., August 02, 2023--Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the second quarter ended June 30, 2023, highlighting record net product sales, with significant year-over-year growth of 26 percent., Headline: Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates, source:Yahoo, summary: Seattle Genetics (SGEN) delivered earnings and revenue surprises of -44.87% and 8.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?, Headline: Seattle Genetics (SGEN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates, source:Yahoo, summary: While the top- and bottom-line numbers for Seattle Genetics (SGEN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",SGEN
177,2023-08-03,"Headline: BMO Capital Sticks to Their Hold Rating for Seagen (SGEN), source:TipRanks, summary: No summary, Headline: Regeneron Pharmaceuticals Inc: A Biotech Powerhouse with High Outperformance Potential, source:GuruFocus, summary: No summary",SGEN
178,2023-08-04,"Headline: RBC Capital Remains a Buy on Seagen (SGEN), source:TipRanks, summary: No summary, Headline: Seagen (SGEN) Gets a Hold from Morgan Stanley, source:TipRanks, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Seagen (SGEN) and Prothena (PRTA), source:TipRanks, summary: No summary, Headline: Analysts’ Opinions Are Mixed on These Healthcare Stocks: Seagen (SGEN) and Prothena (PRTA), source:TipRanks, summary: No summary, Headline: Morgan Stanley Reiterates Seagen (SGEN) Equal-Weight Recommendation, source:Fintel, summary: nan",SGEN
179,2023-08-05,"Headline: 2023 shaping up to be biggest year for biopharma M&A since pandemic, source:Seeking Alpha, summary: No summary",SGEN
180,2023-08-06,"Headline: 3 Cheap Long-Term Stocks That Smart Investors Will Snap Up Now, source:InvestorPlace, summary: No summary, Headline: Pfizer (NYSE:PFE) Seeks Greener Pastures to Boost Sales, source:TipRanks, summary: No summary",SGEN
181,2023-08-07,"Headline: Skanska signs contract with Seagen to build facility in Washington, USA for USD 215 M, about SEK 2.25 billion, source:Finnhub, summary: Skanska has finalized a contract with Seagen to construct a 25,000 square meter biomanufacturing facility for the global biotechnology company.
The facility will include manufacturing, storage,...",SGEN
182,2023-08-08,"Headline: Pfizer Stock’s (NYSE:PFE) Future: Not as Bleak as You’d Think, source:TipRanks, summary: No summary",SGEN
183,2023-08-10,"Headline: BAKER BROS. ADVISORS LP Acquires Significant Stake in Mereo BioPharma Group PLC, source:GuruFocus, summary: No summary, Headline: If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,600 Today, source:Benzinga, summary: No summary",SGEN
184,2023-08-13,"Headline: Horizon Therapeutics, Activision among best bets for M&A deals to close, source:Seeking Alpha, summary: No summary",SGEN
185,2023-08-14,"Headline: Yale University's Q2 2023 Investment Update: A Deep Dive into the Portfolio, source:GuruFocus, summary: No summary, Headline: PRIMECAP Management's Q2 2023 Portfolio Update, source:GuruFocus, summary: No summary",SGEN
186,2023-08-15,"Headline: Seagen's Positive Trial Outcomes: Analyst Says The Update Might Double Tukysa's Current Market, source:Benzinga, summary: No summary",SGEN
187,2023-08-16,"Headline: Seagen: TUKYSA  trial in combo with Kadcyla meets primary endpoint of PFS, source:Thefly.com, summary: No summary, Headline: Seagen says 'OS, data, a secondary endpoint, are not yet mature', source:Thefly.com, summary: No summary, Headline: Seagen Tukysa combo breast cancer treatment successful in phase 3, source:Seeking Alpha, summary: No summary, Headline: Win For Pfizer? Seagen's Cancer Combo Therapy Hits Primary Goal In Late-Stage Breast Cancer Study, source:Benzinga, summary: No summary, Headline: Seagen's breast cancer therapy Tukysa succeeds in late-stage study, source:Alliance News, summary: No summary, Headline: Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer, source:Yahoo, summary: BOTHELL, Wash., August 16, 2023--Seagen Inc. (Nasdaq: SGEN) today announced that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®) met its primary endpoint of progression-free survival (PFS). Patients in the trial had unresectable locally advanced or metastatic human epidermal growth factor receptor 2-positive (HER2-positive) breast cancer and had received previous treatment with a taxane and trastu",SGEN
188,2023-08-17,"Headline: BAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics Inc, source:GuruFocus, summary: No summary",SGEN
189,2023-08-19,"Headline: How To Invest In The Healthcare Sector, source:TalkMarkets, summary: No summary",SGEN
190,2023-08-22,"Headline: Seagen Moves Up In Market Cap Rank, Passing Simon Property Group, source:The Online Investor, summary: No summary, Headline: Notable Wednesday Option Activity: SGEN, ARCB, HSY, source:Stock Options Channel, summary: No summary",SGEN
191,2023-08-24,"Headline: Top Merger Stocks Held By Fund Managers, Mid-Q3 2023, source:SeekingAlpha, summary: Horizon Therapeutics remains top stock held by merger-focused funds for the third consecutive quarter. Read more about top merger stocks held by fund managers.",SGEN
192,2023-08-25,"Headline: Here's How Much You Would Have Made Owning Seagen Stock In The Last 10 Years, source:Benzinga, summary: No summary",SGEN
193,2023-08-28,"Headline: Horizon Therapeutics jumps after FTC pauses Amgen challenge for settlement talks, source:Seeking Alpha, summary: No summary",SGEN
194,2023-08-30,"Headline: Biotech Alert: Searches spiking for these stocks today, source:Thefly.com, summary: No summary, Headline: Genmab Is Down To Attractive Levels, source:SeekingAlpha, summary: Genmab's stock is down 15% since late 2022 highs. Dependence on Darzalex will decrease considerably in the following years. Find out why GMAB stock is a Buy., Headline: Notable Thursday Option Activity: SGEN, GPRE, QTRX, source:Stock Options Channel, summary: No summary, Headline: Tracking Baker Brothers Portfolio - Q2 2023 Update, source:SeekingAlpha, summary: Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. Click here for a detailed analysis.",SGEN
195,2023-08-31,"Headline: Analysts Offer Insights on Healthcare Companies: Seagen (SGEN) and Gain Therapeutics (GANX), source:TipRanks, summary: No summary, Headline: Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors, source:SeekingAlpha, summary: Pfizer's bid to acquire Seagen could reshape pharma. Investors eye a potential 10.6% return in <6 months, pending FTC approval. Find out more about the M&A.",SGEN
196,2023-09-01,"Headline: Horizon Therapeutics gains amid reports FTC settled with Amgen over $28B deal, source:Seeking Alpha, summary: No summary, Headline: Horizon Therapeutics gains after FTC settles with Amgen over $28B deal  (update), source:Seeking Alpha, summary: No summary, Headline: Horizon Therapeutics gains afer FTC settles with Amgen over $28B deal  (update), source:Seeking Alpha, summary: No summary, Headline: Why Is Seattle Genetics (SGEN) Up 6.5% Since Last Earnings Report?, source:Yahoo, summary: Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",SGEN
